Ex­pand­ing on in­jectable schiz­o­phre­nia fran­chise, J&J se­cures nod for first twice-year­ly treat­ment

Schiz­o­phre­nia, like any psy­chi­atric con­di­tion, can be no­to­ri­ous­ly dif­fi­cult to treat. But J&J’s Janssen unit is cham­pi­oning a new ap­proval in the in­di­ca­tion Wednes­day, one it says of­fers long-last­ing ef­fects.

The FDA has OK’ed a twice-year­ly in­jectable treat­ment for schiz­o­phre­nia, J&J an­nounced Wednes­day, an an­tipsy­chot­ic known as six-month paliperi­done palmi­tate. J&J will mar­ket the drug as In­ve­ga Hafy­era, mark­ing the first ap­proved schiz­o­phre­nia ther­a­py to be ad­min­is­tered in half-year in­ter­vals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER